Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

ANVS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Annovis Bio, Inc.NYSE: ANVS

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $18.01M rose 186.7% year over year, ahead of the +64.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 85.6% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +186.7% holds above the trailing-twelve-month pace of +64.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.01M+85.6% QoQ
Last fiscal yearDec 2025
$29.7M+11.2% YoY
LTMMar 2026
$41.42M+64.6% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+186.7%——
1 year+11.2%——
3-year CAGR+5.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
29.7M USD
Year-over-year change
+11.2%
4-year CAGR
+19.6%

Operating Expenses vs competitors

How ANVS compares with its peers on the latest reported figures

  • ANVS's LTM Mar 2026 operating expenses of $41.42M is the 2nd highest of the 6 companies compared; the peer median is $25.93M.
  • Its year-over-year change of +64.6% is the highest of 6, against a peer median of -18.0%.
  • Over three fiscal years its annual growth of +5.2% compares with a peer median of +1.1%.
ANVS Competitors Peer median
Operating Expenses for ANVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$81.5M +5.0%+50.5%307.0%
ANVSAnnovis Bio, Inc.LTM Mar 2026$41.42M +64.6%+5.2%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$28.96M -18.0%-8.9%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$25.93M -40.9%+1.1%73.9%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$25.79M +39.9%+14.5%—
PYPDPolyPid Ltd.LTM Mar 2026$16.09M -45.1%-3.9%—
Peer median (excluding ANVS) $25.93M-18.0%+1.1%190.4%

Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.48M16.52M38.79M20M25.22M
Selling, General & Admin6.06M9M6.24M6.7M4.48M
Operating Expenses14.54M25.51M45.04M26.69M29.7M
Depreciation & Amortization00000
EBITDA(14.5M)(25.33M)(56.2M)(22.74M)(28.85M)
EBITDA Margin—————
Operating Income(14.54M)(25.51M)(45.04M)(26.69M)(29.7M)
Operating Margin—————
Interest Income13.34K182.71K667.9K331.85K699.06K
Interest Expense0001.85M0
Other Income / Expenses50.09K182.71K(11.17M)2.1M841.06K
Income Before Tax(14.49M)(25.33M)(56.2M)(24.59M)(28.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(14.49M)(25.33M)(56.2M)(24.59M)(28.85M)
Net Margin—————
EPS (Basic)(1.90)(3.10)(6.23)(2,018.50)(1.40)
EPS (Diluted)(1.90)(3.10)(6.23)(2,009.77)(1.40)
Weighted Avg Shares7.63M8.16M9.02M12.18M20.55M
Weighted Avg Shares (Diluted)7.63M8.16M9.02M12.24M20.55M

Annovis Bio, Inc.

NYSE:ANVS

Intrinsic Alpha fair value

Locked

Current Price

$1.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.